Literature DB >> 2566965

Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.

S J McKenzie1, P J Marks, T Lam, J Morgan, D L Panicali, K L Trimpe, W P Carney.   

Abstract

A series of monoclonal antibodies specific for the extracellular domain of the human neu gene product (p185) have been produced. The generation of these monoclonal antibodies, and their biochemical and immunological characterization is described. The immunization protocol utilized a series of injections of NIH3T3 cells, cyclophosphamide, and a neu transfected NIH3T3 cell line (designated 18-3-7) which expressed the full length human neu-encoded protein. This immunization regimen induced an immune response to the extracellular portion of p185 on the 18-3-7 cells. A panel of ten hybridomas were identified which secreted monoclonal antibodies with a variety of epitope specificities, and reacted with p185 in a number of different experimental formats. As the neu gene product has been associated with human breast cancers, a series of monoclonal antibodies such as these could prove useful in the diagnosis, prognosis and/or treatment of these human malignancies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566965

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

Authors:  I Stancovski; E Hurwitz; O Leitner; A Ullrich; Y Yarden; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 2.  Type I receptor tyrosine kinases as targets for therapy in breast cancer.

Authors:  J Baselga; J Mendelsohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

3.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

4.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 5.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

Review 6.  Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Authors:  Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

7.  Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis.

Authors:  J Y Rao; G P Hemstreet; R E Hurst; R B Bonner; P L Jones; K W Min; Y Fradet
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas.

Authors:  W Vogel; R Kath; H Kosmehl; E Olschowsky; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

9.  The APC gene product in normal and tumor cells.

Authors:  K J Smith; K A Johnson; T M Bryan; D E Hill; S Markowitz; J K Willson; C Paraskeva; G M Petersen; S R Hamilton; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

Authors:  E Hurwitz; I Stancovski; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.